H. Westley Phillips, MD, joined us to provide clinical pearls regarding the early identification of drug-resistant epilepsy patients in the primary care setting. Drug-resistant epilepsy remains a ...

A discussion of tips and recommendations general providers can use when evaluating ADHD in pediatric patients. Pediatricians play a vital role in the management of ...

With the decision, Kebilidi becomes the first FDA-approved gene therapy for AADC deficiency, and is indicated for adult and pediatric patients. The first gene therapy for for the treatment of aromatic ...

A resubmission Biologics License Application for prademagene zamikeracel (pz-cel) as a potential treatment for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted by the FDA, according ...

Among extremely preterm infants who were receiving surfactant, early intratracheal budesonide could have little to no effect on survival free of bronchopulmonary dysplasia (BPD), according to findings ...

In this video discussion, David Turkewitz, MD, offers clinical pearls to reduce the risk of SIDS and reviews the updated 2022 guidelines from the AAP. David Turkewitz, MD, medical director of Newborn ...

A key update includes providing CPR with rescue breaths and chest compressions to all persons in cardiac arrest after water removal. The American Academy of Pediatrics (AAP) and the American Heart ...

Investigators of a recent study published in JAMA Psychiatry found that adolescents who used cannabis ended up reporting a greater number of psychosis spectrum symptoms and more distress compared to ...

The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025. VAX-31 (Vaxcyte), an infant and adult investigational ...

Data stems from the first 4 patients dosed in a low-dose cohort of an ongoing phase 1/2 open-label trial. NGN-401 (Neurogene), an investigational AAV9 gene therapy being developed as a 1-time ...

The Prescription Drug User Fee Act (PDUFA) date for Dermavant's (now part of Organon) tapinarof cream, 1% (VTAMA) to treat atopic dermatitis in adults and children aged 2 years and up, has been ...

Rakesh Jain, MD, MPH, notes that with increasing ADHD trends, a newly-available and FDA-approved non-stimulant tool can help treat more patients. In this Contemporary Pediatrics video interview, ...